Elucidation of etiology of gastric cancer:A studyon epigenetic silencing of TCF4 gene by Jan, Rabia Farooq (Scholar) et al.
Elucidation of etiology of gastric cancer:
A study on epigenetic silencing of TCF4 gene
Dissertation Submitted for the Award of the Degree
of
Master of Philosophy in Biochemistry
By
Rabia Farooq
UNDER THE JOINT SUPERVISION OF
Prof. Sabhiya Majid
Dr. Shajrul Amin
DEPARTMENT OF BIOCHEMISTRY
GOVERNMENT MEDICAL COLLEGE, SRINAGAR
(RESEARCH CENTRE, UNIVERSITY OF KASHMIR)
THROUGH
DEPARTMENT OF BIOCHEMISTRY
FACULTY OF BIOLOGICAL SCIENCES
UNIVERSITY OF KASHMIR
(NAAC Accredited Grade “A”)
Srinagar- 190006(J&K)
www.kashmiruniversity.ac.in
www.biochemku.org.in
2013
Department of Biochemistry
University of Kashmir
Hazratbal, Srinagar-190006
CERTIFICATE
Certified that the work embodied in the dissertation entitled “Elucidation
of etiology of gastric cancer: A study on epigenetic silencing of TCF4 gene”
has been carried out by Ms. Rabia Farooq under the joint supervision of
Prof. Sabhiya Majid and Dr. Shajrul Amin and the work is suitable for the
award of M.Phil degree in Biochemistry.
It is further certified that no work under this heading has previously been
submitted to the University of Kashmir for the award of any degree or diploma
to the best of our belief.
Prof. Sabhiya Majid
Supervisor
Professor & Head
Department of Biochemistry
Govt Medical College Srinagar
Dr. Shajrul Amin
Co-Supervisor
Sr. Assistant Professor
Department of Biochemistry
University of Kashmir
Prof. Mohammad Afzal Zargar
Head
Department of Biochemistry
University of Kashmir
Department of Biochemistry
University of Kashmir
Hazratbal, Srinagar-190006
DECLARATION
I, Rabia Farooq, declare that the work embodied in this dissertation entitled
“Elucidation of etiology of gastric cancer: A study on epigenetic silencing of
TCF4 gene by promoter hypermethylation” has been carried out by me in the
Department of Biochemistry, Government Medical College, Srinagar (Research
Centre University of Kashmir) and Department of Biochemistry, University of
Kashmir, Srinagar and is original. The work embodies the results of my observations
which are advancement to the previous knowledge in the subject.
Place: Srinagar Rabia Farooq
Date:
DEDICATED TO MY
PARENTS
Who cherished my dreams through sacrifice
TABLE OF CONTENTS
Page No.
Acknowledgement i-ii
Abbreviations iii-v
List of Tables vi
List of Figures vii
Abstract viii-ix
Chapter 1 INTRODUCTION 1-3
Chapter 2 REVIEW OF LITERATURE 4-19
2.1 Gastric Cancer 4
2.1.1 Symptoms 5
2.1.2 Types of Gastric Cancer
2.2.2.1 Intestinal type
2.2.2.2 Diffuse type
5
5
5-6
2.1.3 Pathology 6
2.1.4 Staging 6
2.1.5 Incidence 9
2.1.6
2.1.7
2.1.8
Risk Factors
Epigenetics
TCF4 Gene
9-11
11-16
17-19
Chapter 3 METHODOLOGY
3.1 Cases
20-25
20
3.1.1 Inclusion Criteria 20
3.1.2 Exclusion Criteria 20
3.2 Controls 21
3.2.1 Inclusion Criteria 21
3.2.2 Exclusion Criteria 21
3.3 Collection of Tissue Samples 21
3.4 Genetic Analysis 21
3.4.1 Extraction of Genomic DNA 21
3.4.2 Qualitative and Quantitative Estimation of DNA 22
3.4.2.1
3.4.2.2
Qualitative Analysis
Quantitative Analysis
22
22
3.5 DNA Modification (Bisulfite Treatment) 23
3.6 Methyl specific PCR (MSP) 23-24
3.7 Statistical Analysis 24
Chapter 4 RESULTS 26-40
4.1 Methylation status of TCF4 gene in cases and control
Cases
26
4.1.1 Cases
4.1.2 Controls
26
26
4.1.3 Extraction of Genomic DNA 26
4.1.4 Qualitative Analysis 26
4.1.5 Quantitative Analysis 26
4.2 Analysis of TCF4 gene promoter Hypermethylation in
cases and controls
27-28
4.3 Relationship between promoter Hypermethylation of
TCF4 gene in males and females
34
Chapter 5 DISCUSSION 41-44
BIBLIOGRAPHY 45- 59
APPENDIX
iACKNOWLEDGEMENT
First and foremost, I take this occasion to thank Allah (SWT) for blessing me
with his grace and taking my endeavor to a successful culmination.
I beat the ray of my illuminant gratitude to my honorable guide Prof. Sabhiya
Majid, Head, Department of Biochemistry, Government Medical College, Srinagar for
her excellent constructive criticism, unceasing encouragement, guidance and
uncountable recommendations that kept the optimism of my desire alive and
lightened. Her supervision taught me to appreciate the value of patience and
sustained efforts in the development of scientific attitude. Besides she also provided
me with all the facilities for research purposes.
I am sincerely thankful to Dr. Shajrul Amin, Sr. Assistant Professor,
Department of Biochemistry, University of Kashmir, my co-guide for her constant
encouragement and appraisals. Her moral support made my work easy. She besides
being a teacher is a nice person. She helped me in compiling the thesis. I cordially
thank her for her gracious attitude towards me, all through the work.
I also attribute cordial thanks to Prof. Bashir Ahmad Ganai who really is a
man of respect; who has been source of inspiration for me. He helped me in
compilation of thesis and gave me every support. Without his encouragement this task
would have been a mere dream for me. He has been very kind to me, besides being a
teacher.
I am sincerely thankful to Prof. Mohammad Afzal Zargar, Head, Department
of Biochemistry, University of Kashmir, Prof. Rafiq Pampori, Principal & Dean
Government Medical College Srinagar and Prof. Akbar Masood, Dean Faculty of
Biological Sciences and former Head Department of Biochemistry, University of
Kashmir, for providing me with all the facilities without which this research could
not have been completed successfully.
I also express my thanks to all esteemed members of the department, Dr. Rabia
Hamid, Dr. Nazir Ahmad Dar and Dr. Shaida Andrabi. I sincerely thank them for
their support and suggestions.
I am indebted to Dr. Rafiqa Eachkoti, Lecturer, Department of Biochemistry,
Government Medical College, Srinagar and Dr. Tabassum Rashid and Mrs. Roohi
Ashraf, Lecturers, Department of Biochemistry, Government Medical College
Srinagar for their valuable suggestions time and again.
Acknowledgement
ii
I am also thankful to the office staff of Department of Biochemistry,
Government Medical College Srinagar and Department of Biochemistry, University
of Kashmir for all the work put in by them to make this research a reality. I am also
thankful to the laboratory staff of Department of Biochemistry, Government Medical
College Srinagar for their selfless support.
I also want to acknowledge the company of my colleagues and seniors Arshid
Mattoo, Arif Akbar, Hilal Wani, Hyder Khan and specially to Haamid Bashir, who
really helped in my work and always stood beside me and all others who were a
constant source of motivation.
Words would not suffice for the constant encouragement, love and affection
of my grandparents, parents, my brother Owais Farooq and my sweet little sister
Ayman Farooq as I could not have come up to this stage without their relentless
support, sacrifice and everlasting blessings. They always used to entertain me when i
was in distress.
I would also like to thank Saju. To imprison his contribution in meagre scope
is a distant possible if not impossible. His spiritual assistance and constant
encouragement and constructive criticism made this dream possible for me.
Besides, I also express my thanks to my friends Ahlam, Nida, Aafia, Adil,
Ishaq, Sumaiya, Arif, Muzamil, Gousia, Abid who always helped me whenever I was
in need.
Rabia Farooq
.
ABBREVIATIONS
iii
AIDS Acquired Immuno Deficiency Syndrome
AJCC American Joint Committee on Cancer
bHLH Basic Helix Loop Helix
bp Base pair
C Cytosine
cag A Cytotoxin associated gene A
CDKN2A Cyclin dependent kinase inhibitor
CHD1 Chromodomain-helicase-DNA-binding protein 1
cm Centimetre
CREB cAMP response element-binding protein
DNA Deoxyribose Nucleic Acid
DNMTs DNA methyl transferases
dNTP Deoxyribose Nucleotide Triphosphate
EBV Epstein Barr Virus
EDTA Ethylene Diaminetetraacetic Acid
Fig. Figure
g Gram
GC Gastric Cancer
GIT Gastrointestinal Tract
GSTP1 Glutathione S-transferase P
µg Microgram
µl Microlitre
µM Micromolar
HCl Hydrochloric Acid
HDAC Histone deacetylase
HDGC Hereditary Diffuse Gastric Carcinoma
ABBREVIATIONS
iv
HIV Human Immunodeficiency virus
HLH Helix Loop Helix
HMG High Mobility Group
HP Helicobacter pylori
HPLC High performance liquid chromatography
HRT Hormone replacement therapy
IARC International Agency for research on cancer
ITF2 Immunoglobin Transcription Factor 2
Kb Kilo base pair
Kd Kilo Dalton
M Molar
MBD Methyl Binding Domains
MeCP1 Methyl-CpG-binding protein
mg Milligram
MgCl2 Magnesium chloride
min Minutes
ml Millilitre
mM milimolar
ng Nanogram
O.D Optical Density
O.R Odds Ratio
oC Degree Celsius
PCR Polymerase Chain Reaction
PHS Pitt Hopkins Syndrome
Rb Retinobalstoma
SAM S –adenosyl methyl transferase
ABBREVIATIONS
v
SDS Sodium Dodecyl Sulphate
sec Second
SKIMS Sheri – Kashmir Institute of Medical Sciences Soura
SMHS Shri Maharaja Hari Singh
SNP Single nucleotide polymorphism
Taq Thermus aquaticus
TCF Transcription Factor
Tm Melting Temperature
5YSR 5 year survival
TNM Tumour node metastasis
TRD Transcriptional repressor domain
U Uracil
UK United Kingdom
UV Ultraviolet
WHO World Health Organisation
vi
LIST OF TABLES
Tables Page No.
Table 1: TNM system of staging (AJCC Staging) manual for Gastric cancer. 8
Table 2: Primer pairs used for amplification of the DNA samples. 25
Table 3: Volume and concentrations of different reagents used in
MSP(Methylation Specific PCR)
25
Table 4: Thermal cycling conditions 25
Table 5: Data representing no. of cases showing promoter hypermethylation
and non-hypermethylation during MSP amplification in gastric
cancer cases confirmed by 2% agarose gel electrophoresis
32
Table 6: Data representing no. of cases showing promoter hypermethylation
and non-hypermethylation during MSP amplification in
histopathologically confirmed normal cases confirmed by 2%
agarose gel electrophoresis
32
Table 7: Data representing no. of cases showing promoter hypermethylation
and non-hypermethylation in male gastric cancer cases and male
controls during MSP amplification confirmed by 2% agarose gel
electrophoresis
35
Table 8: Data representing no. of cases showing promoter hypermethylation
and non-hypermethylation in female gastric cancer cases and female
controls during MSP amplification confirmed by 2% agarose gel
electrophoresis
37
Table 9: Data representing no. of cases showing promoter hypermethylation
and non-hypermethylation in male and
female gastric cancer cases during MSP amplification confirmed by
2% agarose gel electrophoresis
39
vii
LIST OF FIGURES
Figures Page No.
Figure 1: Adenocarcinoma of intestinal type gastric carcinoma. 7
Figure 2: Carcinoma of diffuse type gastric cancer 7
Figure 3: Mechanism of transcription repression 14
Figure 4: Chromosomal translocation of Human TCF4 17
Figure 5: Representation of cytosine conversion to uracil 23
Figure 6: Representative gel picture showing the integrity of the genomic
DNA on 1.0 % Agarose. 27
Figure 7: The cancer DNA samples amplified by MSP. 29
Figure 8: The Normal DNA samples amplified by MSP 30
Figure 9: Normal DNA samples amplified by MSP. 31
Figure 10: Histogram representing hypermethylated and
nonhypermethylated cases of gastric cancer and
histopathologically confirmed normal controls
33
Figure 11: Histogram representing hypermethylated and
nonhypermethylated cases of male gastric cancer and
histopathologically confirmed male normal controls
36
Figure 12: Histogram representing hypermethylated and
nonhypermethylated cases of female gastric cancer and
histopathologically confirmed female normal controls
38
Figure 13: Histogram representing hypermethylated and
nonhypermethylated cases of male and female gastric cancer
samples.
40
ABSTRACT
ABSTRACT
viii
Gastric cancer (GC) is the second most common cancer among
population, and it causes 800,000 deaths worldwide annually. Most deaths from
stomach cancer occur in men of age 55 and older. The risk for developing
gastric cancer appears to be affected by several factors. People with a family
history of gastric cancer have an increased risk of developing this disease.
Besides, Helicobacter pylori infection also can be the cause of this disease.
Cancer development is caused by series of genetic alterations in genes like in
oncogenes, tumor suppressor genes, DNA repair genes, etc. Besides epigenetic
alterations are also taken into consideration. The TCF4 gene is frequently found
to be inactivated by promoter methylation in a broad range of human tumors.
The TCF4 gene belongs to a family of genes called bHLH . It is involved in the
development and functioning of many different cell types. Exogenous expression
of bHLH family proteins can promote cell cycle arrest and apoptosis.
The aim of this study was to identify promoter hypermethylation in CpG
islands of TCF4 gene in gastric cancer patients among the Kashmiri population.
In this study methylation status of CpG islands in the TCF4 gene in
histopathologically confirmed 50 gastric cancer samples and histopathologically
confirmed 30 normal gastric tissues was analyzed. Methylation Specific
Polymerase (MSP) chain reaction was used for analysis of TCF4 promoter
hypermethylation status. In the current study, it was found that 66% (33/50) of
the cases had TCF4 promoter hypermethylation while as 34% (17/50) of the
cases were unmethylated. The study also revealed that 20% (6/30) of the
controls also had promoter hypermethylation of CpG islands of TCF4 gene and
80% (24/30) did not show promoter hypermethylation of CpG islands of TCF4
gene. The association of promoter hypermethylation with gastric cancer was
evaluated by χ
2 (Chi square) test with Odds ratio and was found to be significant
(P=0.0001, Odds ratio=17.47, 95%C.I=3.620-84.32). Among 33 male cases and
17 female cases, the association of promoter hypermethylation with gastric
cancer was evaluated using Fischer’s exact test and was found to be significant
in both males and females. However, the occurrence of TCF4 promoter
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hypermethylation was found to be unequally distributed in males and females
with more frequency in males than females but the difference was not
statistically significant (p= 0.08).
From this hypermethylation study it is inferred that TCF4 gene promoter
is often methylated in gastric cancer patients and thus these results suggest that
TCF4 promoter hypermethylation may contribute to the process of
carcinogenesis in gastric cancer. The results also suggest that hypermethylation
of TCF4 gene can be designated as epigenetic biomarker for the screening,
diagnosis and prognosis of gastric cancer.
CHAPTER: 1
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Cancer (medical term: malignant neoplasm) is a general term for large group of
diseases characterised by self sufficiency in growth signals, insensitivity to growth
inhibitory (antigrowth signals),evasion of programmed cell death (apoptosis), limitless
replicative potential, sustained angiogenesis and tissue invasion (Hanahan and
Weinberg, 2000). Cancer affects people of all ages, and a few types of cancer are more
common in children. Cancer occurs due to failure of regulation of genes which control
cell growth and differentiation (Croce, 2008). The affected genes include oncogenes
and tumor suppressor genes. Malignant transformation can also occur through the
formation of novel oncogenes, the inappropriate over-expression of normal oncogenes,
or by the under-expression of tumor suppressor genes. Thus, changes in many genes are
required to transform a normal cell into a cancer cell (Knudson, 2001). Genetic changes
can occur at different levels and by different mechanisms like the gain or loss of an
entire chromosome during mitosis, mutations, deletion or gain of a portion of a
chromosome, translocation, inversion etc. In the global incidence of cancer, esophageal
cancer is the sixth, colorectal cancer is the third, and gastric cancer is the second most
common tumor (Chan and Rashid, 2006). GIT cancers account for about 20% of all
cancers worldwide.
Gastric cancers are typically carcinomas which arise from the epithelium, or
surface lining, of the stomach. It starts from one of the common cell types found in the
lining of the stomach. It has a very poor prognosis with 800,000 deaths per year
(Cancer Fact sheet, 2009). Gastric cancer is asymptomatic disease and its prognosis is
related to tumor extent and includes both nodal involvement and direct tumor extension
beyond the gastric wall (Nakamura et al., 1992; Slewart et al., 1998).
DNA methylation is one of the most commonly occurring epigenetic event
taking place in the mammalian genome. In prokaryotes DNA methylation provides a
way to protect host DNA from digestion by restriction endonucleases that are designed
to eliminate foreign DNA, and in eukaryotes it functions in the regulation/control of
gene expression (Costella et al., 2001). DNA methylation occurs in promoter CpG
islands which are 0.5-2 kb regulatory regions, present in the 5'- region of approximately
40% of promoters of mammalian genes (Jones and Laird, 1999; Esteller, 2002;
Herman and Baylin, 2003; Fatemi et al., 2005). CpG dinucleotide content in CpG
islands is about of at least 60%, whereas the rest of the genome has much lower CpG
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frequency, a phenomenon called CG suppression (Feil et al., 2007). These CpG islands
are targets of methylation for their proper expression. It has been demonstrated that
aberrant DNA methylation is a widespread phenomenon in cancer and may be among
the earliest changes to occur during oncogenesis (Stirzaker, 1997). It is now realized
that CpG island hypermethylation also causes change in chromatin structure and
histone modifications which includes histone H3 and H4 deacetylation (Johnstone,
2002) histone methylation (Kondo et al., 2003), histone H4 sumoylation (Shiio and
Eisenman 2003) and reduced histone H3 lysine 4 methylation (Boggs et al., 2002;
Liang et al., 2004), collectively resulting in a transcriptionally silenced state,
phenomenon being termed as epigenetic silencing. Epigenetics has evolved as a rapidly
developing area of research. The ability to detect and quantify DNA methylation
efficiently and accurately has become essential for the study of cancer, gene expression,
genetic disease, as well as many other important aspects of biology. To date a number
of methods have been developed to detect/quantify DNA methylation including HPLC
(Fraga et al., 2000) and methylation sensitive arbitrarily primed PCR (Gonzalgo et al.,
1997). However the most common technique used today remains the bisulfite
conversion method (Frommer, 1992). This method is ideal for mapping the normal and
aberrant patterns of methylation. This technique involves treating methylated DNA
with bisulfite which converts unmethylated cytosines into uracil without causing any
change in methylated cytosines. Once converted the methylation profile of the DNA
can be determined by PCR amplification followed by DNA sequencing.
The ubiquity of DNA methylation changes has opened the way to a host of
innovative diagnostic and therapeutic strategies. Aberrant DNA methylation patterns
provide three powerful diagnostic applications as classification markers, as sensitive
detection markers, and risk assessment markers as the field moves to human epigenome
projects. Besides acting as diagnostic markers, epigenetic changes in cancer cells also
provide novel targets for drug therapy (Stirzaker et al., 1997; Gerasimova et al., 2001;
Di Croce et al., 2002; Gonzalez et al., 2003). Recent advances in research makes DNA
methylation markers as powerful future tools in the clinic as the field of cancer
epigenetics is evolving rapidly on several fronts (Jones and Baylin, 2002; Fruhwald,
2003; Laird, 2005). Its wide applicability and potential importance will possibly lead to
increasing clinical impact in the near future (Hanash, 2004). Thereby, advances in our
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understanding of chromatin structure, histone modification, transcriptional activity and
DNA methylation have resulted in an increasingly integrated view of epigenetics.
Epigenetic silencing through DNA methylation can begin very early in tumor
progression and may affect multiple genes involved in different cellular pathways
including cell cycle control, DNA repair and many others (Baylin et al., 1998; 2001).
Promoter hypermethylation can cause transcriptional inactivation/silencing of various
cell cycle control genes, tumor suppressor genes like RASSF1A, p16, hMLH1, CDH1
etc. Many genes are modified in stomach cancer and one of such gene is TCF4. TCF4
is a protein coding gene which codes for protein Tcf4 that binds to specific regions of
DNA and helps to control the activity of many other genes, which helps in cell
differentiation, DNA dependent transcription, initiation etc. On the basis of this action,
the TCF4 protein is known as a transcription factor. TCF4 is a downstream target of the
Wnt/β-catenin pathway and is found to be deregulated in human colon cancers (Kolligs,
2002). Interaction of nuclear β-catenin and TCF4 is believed to trigger the transcription
of multiple cancer associated genes, including CD44, cyclin D, c myc. TCF4 null mice
show developmental defects of small intestine (Korinek et al., 1998).
TCF4 gene is located on chromosome 18q21.2 and spans 437 kbp. Although the
expression of TCF4 is ubiquitous, its levels vary considerably between
tissues. Epigenetic mechanisms of gene activation, including promoter
hypermethylation, are undoubtedly important in cancer development and represent an
alternative means of inactivating important genes. However, before accepting the
conclusion that promoter hypermethylation is invariably the cause of gene inactivation,
it is worth evaluating the data a bit more critically. Nevertheless, the standard of proof
for establishing that hypermethylation of promoter of any given gene has a critical role
in loss of gene expression and cancer development should probably be set quite high,
regardless of whether the gene is a cell cycle regulatory gene or tumor suppressor gene.
The present study is an attempt to analyze the TCF4 gene promoter
hypermethylation in gastric carcinoma patients of Kashmir valley, so that it can be used
as epigenetic marker for the screening of gastric cancer. This may help in prognosis and
diagnosis of the disease so that further preventive measures could be taken.
CHAPTER:2
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2.1 Gastric Cancer
Advances in diagnostic and treatment technologies have resulted in excellent long
term survival for gastric cancer but it is still the second most cause of cancer death in
the world (Tominaga, 1998). Gastric cancers are typically carcinomas which arise from
the epithelium of the stomach. About 95% of stomach cancers are of adenocarcinoma
type (Si-Chun et al., 1965), which starts from one of the common cell types found in
the lining of the stomach. It is a common cancer of the digestive tract worldwide and is
common in Japan (Eurogast study group, 1993), Chile, and Iceland, although it is
uncommon in the United States. Several different types of cancer can occur in the
stomach. There are number of rarer types of cancer that can affect the stomach. These
include:
 Soft tissue sarcomas, of which the commonest are leiomyosarcomas
 Gastrointestinal stromal tumours .
 Lymphomas such as mucosa associated lymphoid tissue lymphomas (4%)
 Carcinoid tumors (3%) (Kumar, 1994)
Gastric cancer has a very poor prognosis. It is more prevalent in males than females
(Jayaramam et al., 2005) mostly over age of 50 years. Stomach cancer tend to develop
slowly over many years. Before a true cancer develops pre-cancerous changes often
occur in the lining of the stomach. These early changes rarely cause symptoms and
often undergoes undetected, so its prognosis is poor. The overall five-year survival rate
(5YSR) is approximately 30%, with most patients dying within the first year of
diagnosis (Macdonald et al., 2004).
Cancers as a group account for approximately 13% of all deaths each year with the
most common being: lung cancer (1.3 million deaths), stomach cancer (803,000
deaths), colorectal cancer (639,000 deaths), liver cancer (610,000 deaths),and breast
cancer (519,000 deaths) (WHO, 2006). Over half of cases occur in the developing
world (Devesa and Silverman, 1978; Jemal et al., 2011). Cancer is regarded as a
disease that must be "fought" to end. The estimates of cancer cases for all sites for
Indian males are 462,408; 497,081 and 534,353 for the years 2010, 2015 and 2020,
respectively. The corresponding estimates of cancer cases for females are 517,378;
563,808 and 614,404. Further, the total cancer cases are likely to go up from 979,786
Chapter. 2 Review of Literature
5
cases in the year 2010 to 1,148,757 cases in the year 2020 (Ramnath Takiar et al.,
2010)
2.1.1 Symptoms
 Abdominal fullness or pain
 Dark stools
 Difficulty swallowing, especially if it increases over time
 Excessive belching
 General decline in health
 Loss of appetite
 Nausea and vomiting
 Premature abdominal fullness after meals
 Vomiting blood
 Weakness or fatigue
 Weight loss (unintentional)
2.1.2 Types of Gastric cancer
This malignancy exists in two principal forms (Lauren, 1965):
 Type I (intestinal)
 Type II (diffuse)
2.1.2.1 Intestinal, expansive, epidemic-type gastric cancer
Is associated with chronic atrophic gastritis, retained glandular structure, little
invasiveness, and a sharp margin and is associated with most environmental risk
factors, carries a better prognosis, and shows no familial history as depicted in fig 1.
2.1.2.2 Diffuse, infiltrative, endemic type gastric cancer
Diffuse gastric cancer or HDGC is a specific type of stomach cancer that tends
to affect much of the stomach rather than staying in one area of the stomach as depicted
in fig 2. This type is also not recognizably influenced by environment or diet, is more
virulent in women, and occurs more often in relatively young patients. The average age
for someone with HDGC to be diagnosed with stomach cancer is 38. HDGC is a
genetic condition, follows an autosomal dominant inheritance pattern, so has a chance
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to be passed from generation to generation in a family. A mutation in CHD1 gene gives
a person an increased risk of developing HDGC and is estimated to be about 65% for
men and 80% for women, besides increases risk for developing other cancers like
lobular breast cancer in women (Becker et al., 1994). It shows scattered cell clusters
with poor differentiation and dangerously deceptive margins.
2.1.3 Pathology
Pathology of tumor is usually reported from the analysis of tissue taken from a
biopsy or surgery. A pathology report will usually contain a description of cell type and
grade.
2.1.4 Staging
Staging is a careful attempt to find out whether the cancer has spread and, if so,
to what parts of the body and how much. It also helps in predicting a patients outlook
(prognosis). Two main ways are the TNM (Tumors/nodes/metastases) system, from the
American Joint Committee on cancer (AJCC staging manual, 2002) as shown in Table
1 and the number system.
Cancer of the stomach can spread directly, via lymphatics, or hematogenously.
Direct extension into the omenta, pancreas, diaphragm, transverse colon or mesocolon,
and duodenum is common. If the lesion extends beyond the gastric wall to a free
peritoneal (i.e, serosal) surface, then peritoneal involvement is frequent. Hematogenous
spread commonly results in liver metastasis. Gastric cancer can spread almost
anywhere in the body, including the liver, lungs, brain, and bones.
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Fig 1: Adenocarcinoma of intestinal type
(Source: Wikipedia)
Fig 2: Gastric carcinoma of the diffuse type
(Source: Wikipedia)
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Table1: TNM system of staging (AJCC staging manual,2002)
AJCC Stage TNM stage TNM stage criteria for gastric cancer
Stage 0 Tis N0 M0 Tis: Tumour confined to mucosa; cancer-in-situ
Stage I-A T1 N0 M0 T1: Tumour invades submucosa
Stage I-B T1 N1 M0 N1:Metastasis to 1-2 regional lymph nodes
T2N0M0 T2:Tumor invades muscularis propia
Stage II-A T3 N0 M0 T3: Tumour invades subserosa or beyond (without other
organs involved)
Stage II-B T4 N0 M0 T4: Tumour invades adjacent organs or perforates the visceral
peritoneum
Stage III-A T1-2N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T1 or T2.
Stage III-B T3-4N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T3 or T4.
Stage III-C T, N2 M0 N2: Metastasis to 4 or more regional lymph nodes. Any T.
Stage IV Any T, any N, M1 M1: Distant metastases present. Any T, any N.
(Source: Wikipedia)
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2.1.5 Incidence:
Cancer is a major burden worldwide but there are marked geographical
variations in frequency and overall incidence. In 2008 approximately 12.7 million
cancers were diagnosed (excluding non-melanoma skin cancers and other non-invasive
cancers) and 7.6 million people died of cancer worldwide (Jemal, 2011). Gastric
carcinoma is one of the most common cancer occurring globally (Parkin et al., 2005)
and second major cause of cancer related deaths in India (Peter and Bernard, 2008).
The incidence of gastric cancer has decreased considerably in US over the past 60 years
(Devesa et al.,1978). Incident rates are high in Japan, China, Chile and Ireland
(Dunham et al., 1968 ). New estimated gastric cancer cases are: 21,320 (13,020 men
and 8300 women) and Deaths: 10540 in US in 2012 (American cancer society: Cancer
facts and figures 2012). Globally the highest rate in males was seen in Japan-
80/100,000 and the lowest rate in Thailand-3/100,000. Among females also the highest
rate of 31/100,000 was in Japan and lowest of 1 in Trivandrum, India (Curado et al.,
2007). In India the high incidence areas includes North-East India ( Phukan et al.,
2001) and Kashmir valley (Khuroo et al.,1992), where environment and dietary habits
play an overwhelming role in the development of stomach cancer over the genetic
factors. Kashmir is a very high risk area of most commonly occurring cancers
particularly cancers of gastrointestinal tract which comprise more than half the
frequency of all the cancers (Shah and Jan, 1990; Mir et al., 2005). In Kashmir,
stomach cancer is the leading one with an average frequency of 19.2 % followed by
esophagus and lung as 16.5 % and 14.6 %, respectively. Stomach ( 23 %) and lung (
21 %) are the leading cancers in men while as esophageal cancer tops (18.3 %) in
women followed by breast cancer (16.6 %) according to statistics obtained from a
period of 5 years ( Jan 2005 to Apr 2010) ( Pandith and Siddiqui , 2012). Incidence of
gastric cancer in Kashmir is three to six times higher than in other states (Khuroo et al.,
1992). Almost two thirds of people with stomach cancer are 65 or older. The risk of a
person developing stomach cancer in their lifetime is about 1 in 114, but is slightly
higher in men than in woman with the ratio of 3.6:1 (Azra and Jan, 1990).
2.1.6 Risk Factors
Cancer is a multifactorial disease so it is hard to explain why one man develops
cancer and another does not. However, we do know that person with certain risk factors
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may be more likely than others to develop stomach cancer (Levin and Dozois, 1991).
Some factors that have been associated with gastric cancer are as follows
 Family history of gastric cancer: Family history is being looked at as a risk
factor for stomach cancer. Brothers, sisters, and children, of people with
stomach cancer have an increased risk of getting it themselves.
 Helicobacter pylori infection (a common bacteria that can also cause stomach
ulcers).
H.P, carcinogen class I (IARC,1994), colonizes the gastric epithelium and causes a
severe inflammatory reaction that depends on factors including host genetic
susceptibility, immune response, age at the time of initial infection, and
environmental and virulence factors such as (cagA) (Wu et al., 2003, Franco et al.,
2008; Umit et al., 2009). The complex interactions among the different types of H.
pylori, inflammation and genetic features of the host could promote a cascade of
morphological events leading to gastric cancer (Correa, 2004).
The Epstein Barr virus (EBV) has also found to be associated with gastric
carcinoma in at least 10% of cases (Takada et al., 2000), is more prevalent in Japan
(19.3%) and Germany (18%) (Takada et al., 2000; Van Beek et al., 2004).
 Dietary Factors: A diet high in starchy foods, salted and smoked foods,
increases the risk of stomach cancer (Sriamporn et al., 2002; Azra, 1995;
Morson, 1995). Stomach cancer levels are very high in Japan where very salty
pickled foods are popular. A preserved food and pickels may also increase risk
of developing cancer. In Kashmir a lot of dietary features and life style are
peculiar, e.g., consumption of hot salted tea, sun-dried vegetables of Brassica
family (Hakh), pickled vegetables (Anchar), dried fish, red chilies, spice cakes
etc. These food items have been found to contain substantial amount of N-
nitroso compounds including N-nitrosopipecolic acid, mono and diamines of
methane and ethane, with several unidentified nonvolatile N-nitroso compounds
(Kumar et al., 1992; Siddiqi et al., 1992; Siddiqi et al., 1998).
 Age: Stomach cancer becomes more common as people get older. Around 95
out of every 100 cases (95%) are diagnosed in people aged 55.
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 History of other cancers: Statistically, men have a slightly increased risk of
stomach cancer if they've had prostate, breast, bladder or testicular cancer.
Women have an increased stomach cancer risk if they've had ovarian, breast or
cervical cancer. Both sexes have an increased risk if they've had food pipe
(esophageal) cancer, non melanoma skin, bowel, non Hodgkin's lymphoma or
thyroid cancer.
 Reduced immunity: People with suppressed immune systems due to infection
with HIV, AIDS, or drugs taken following an organ transplant, have double the
risk of stomach cancer compared to other people. This may be because they
have an increased risk of infection such as Helicobacter pylori.
 Hormone replacement therapy (HRT): Women who take hormone replacement
therapy have a reduced risk of stomach cancer. But HRT increases the risk of
some other types of cancer, including breast cancer.
 History of an adenomatous gastric polyp larger than 2 centimeters
 History of chronic atrophic gastritis
 History of pernicious anemia
 Anti inflammatory drugs: Studies showed that people who regularly take non
steroidal anti inflammatory drugs appear to have a slightly lower risk of
stomach cancer e.g: aspirin, ibuprofen or Nurofen.
 Smoking: Cigarette smoke contains many carcinogens. Smoking can increase
the risk of stomach cancer. About 1 in 5 stomach cancers (20%) in the UK is
thought to be caused by smoking. People who smoke have around twice the risk
of developing stomach cancer compared to non smokers. The risk falls if you
stop smoking. If smokers have HP infection, they may have more than 10 times
the risk of non smokers without HP infection.
Besides these risk factors, cancer can arise due to cumulative effect of mutations in
various regulatory genes, or from epigenetic changes in DNA (Fearon et al., 1990;
Vogelstein et al., 1988; Mustafa et al., 2007).
2.1.7 Epigenetics
Epigenetics has been found to be major concern for all type of cancers.
Epigenetics can be described as a stable alteration in gene expression potential that
takes place during development and cell proliferation, without any change in gene
Chapter. 2 Review of Literature
12
sequence. This change, though heritable, is reversible, making it a therapeutic target.
Recent studies have shown that epigenetics plays an important role in viral infections,
(Baylin, 1997) cancer biology (Singal and Ginder, 1999; Jones and Baylin, 2002)
activity of mobile elements, (Costello and Plass, 2001) somatic gene therapy, cloning,
transgenic technologies, genomic imprinting, developmental abnormalities, mental
health, and X-inactivation (Amir et al., 1993; Laird, 2003). Epigenetic changes may
involve DNA methylation, Histone acetylation, etc. DNA methylation is one of the
most common epigenetic change. DNA methylation is a covalent chemical
modification, resulting in the addition of a methyl (CH3) group at the carbon 5 position
of the cytosine ring. Even though most cytosine methylations occur in the sequence
context 5’CG 3’ (also called the CpG dinucleotide), some involves CpA and CpT
dinucleotides (Ramsahoye et al., 2000). The human genome contains regions of
unmethylated segments interspersed by methylated ones (Antequera and Bird, 1993).
Approximately half of all the genes (housekeeping genes and genes with tissue specific
patterns of expression) in humans have CpG islands (Bird, 1986; Singal and Ginder,
1999). DNA methylation is brought about by a group of enzymes known as the DNA
methyltransferases (DNMTs). The DNMTs known to date are DNMT1, DNMT1b,
DNMT1o, DNMT1p, DNMT2, DNMT3A, and DNMT3b with its isoforms, and
DNMT3L (Robertson, 2002). DNMT1 has de novo as well as maintenance
methyltransferase activity, and DNMT3A and DNMT3b are powerful de novo
methyltransferases (Costello and Plass, 2001). The methylation profile of the cell is
exquisitely controlled during development. Methylation patterns are established in the
early embryo with initial demethylation of the parental DNA in the first few cell
divisions after fertilization, followed by de novo methylation of specific CpG sites
between the eight cell stage and blastocyst implantation (Monk, 1990; Howlett and
Reik, 1991; Mayer et al.,2000; Reik et al., 2001). An apparent interplay between de
novo methylation and demethylation at each cell division gives rise to a heterogenous
pattern of methylation for any one molecule (Warnecke et al., 1998; Warnecke and
Clark, 1999), so it has become clear that the methylation state of any one CpG site is
not always maintained. The other machinery of methylation includes demethylases,
methylation centers triggering DNA methylation, and methylation protection centers
(Costello and Plass, 2001; Szyf, 2003).
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DNA methylation in mammals is thought to be important for gene regulation
control. Methylation within gene regulatory regions such as promoters and enhancers
generally affects several important signaling pathways that are frequently activated in
cancer cells by suppressing their function. For example, most promoter regions that are
methylated in vitro, either from tissue-specific or CpG island associated genes, show
reduced expression after transfection. Methylation induced suppression is thought to
occur either by the blocking of transcription factor binding (Iguchi and Schaffner,
1989; Molloy and Watt, 1990) and/or by formation of an inactive chromatin state by
histone modification (Nan et al., 1998; Bird and Wolffe, 1999; Magdinier and Wolffe,
2001). However, it is still unclear whether methylation directly elicits gene inactivation
or is a consequence of gene silencing. For example, CpG islands on the inactive X
chromosome are methylated subsequent to gene silencing. Several mechanisms have
been proposed to account for transcriptional repression by DNA methylation. The first
mechanism involves direct interference with the binding of specific transcription
factors to their recognition sites in their respective promoters. Several transcription
factors, including AP-2, c-Myc/Myn, the cyclic AMP-dependent activator CREB, E2F,
and NFkB, recognize sequences that contain CpG residues, and binding of each has
been shown to be inhibited by methylation. (Tate and Bird, 1993; Singal and Ginder,
1999).
The second mode of repression involves a direct binding of specific
transcriptional repressors to methylated DNA or by directly preventing binding of
transcriptional activators to DNA. The DNA methylation signals are analyzed by the
MBDs, the target being the 5' methylated CpG sequence (Singal et al., 1997; Singal et
al., 2001 and Prokhortchouk and Hendrich, 2002). MeCP1 and MeCP2 were the first
two protein complexes identified (Klose and Bird, 2006).These contain MBD and TRD
capable of silencing transcription. The TRD domain interacts with SIN3A - a
transcriptional corepressor, suggesting a link between transcriptional repression,
histone deacetylation and DNA methylation. The details of mechanism of
transcriptional silencing is shown in figure 3.
Chapter. 2
Figure 3. Repression of transcription via CpG dinucleotide methylation. Promoter
sequence binds transctiption factors (TFs) and RNA polymerase II (POL II)
that initiates transcription (A). Methylation of CpG within promoter binding
site directly inhibits
Methylated DNA binds m5CpG binding (MeCPs) and (MBDs) forming spatial
obstacle that prevents binding of TFs to promoter sequence.
Review of Literature
requirement of TFs and represses transcription (B).
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Hypermethylation in cancer reports far outnumber the reports of
hypomethylation in cancer. The first tumor suppressor gene found to be silenced
through promoter hypermethylation was Rb1 (Sakai et al., 1991). DNA
hypermethylation is considered as frequent event as mutations occurring within the
coding region of these genes. Active transcription, active demethylation, replication
timing, and local chromatin structure prevents access to the DNA methyltransferase and
thus acts as protective mechanisms to prevent hypermethylation of the CpG islands
(Clark and Melki, 2002). The genes that are susceptible are the genes involved in cell
cycle regulation (p16INK4a, p15INK4a, Rb, p14ARF ) genes associated with DNA
repair (BRCA1, MGMT), apoptosis (DAPK, TMS1), drug resistance, detoxification,
differentiation, angiogenesis, and metastasis. GSTP1 gene, is found to be
hypermethylated in more than 90% of prostate cancers but is largely unmethylated in
acute myeloid leukemia. (Lee et al.,1994; Melki et al., 1999). The mechanisms
involved in targeting of methylation to specific genes in cancer remain to be
determined.
Besides hypermethylation, hypomethylation is also observed in a wide variety
of malignancies (Feinberg and Vogelstein, 1983; Kim et al., 1994). Genome wide
hypomethylation is believed to cause inappropriate proto-oncogene activation and
transcription, and malignant transformation (Jones and Baylin, 2002; Feinberg and
Tycko, 2004). Hypomethylation of CpGs was reported in colorectal cancers by Fearon
et al. in 1983 (Feinberg and Vogelstein, 1983). It is common in solid tumors such as
metastatic hepatocellular cancer, (Lin et al., 2001) in cervical cancer, (Kim et al., 1994)
prostate tumors, (Bedford and Helden, 1987) and also in hematologic malignancies
such as B-cell chronic lymhocytic leukemia (Ehrlich, 2002). Hypomethylation of
retrotransposons causes transcriptional activation and has been found in many types of
cancer, such as urinary bladder cancer (Jurgens et al., 1996). Inadequate dietary folate
has been implicated in the development of several types of cancers (Duthie et al.,
2004). One proposed mechanism is that folate deficiency might induce DNA
hypomethylation. High alcohol intake reduces intracellular levels of SAM thus causes
DNA hypomethylation, besides cleaves folate, impair folate absorption and increases
folate excretion (Kenyon et al., 1998).
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The detection of epigenetic alteration in tumorigenesis has led to a host of
innovative diagnostic and therapeutic strategies. Epigenetic changes have been detected
in the body fluids of almost every organ system in cancer patients (Laird, 2003). This
would thus help us to know patients response to treatment and predicting survival.
CDKN2A gene was found to be hypermethylated in 61.1% of colon tumor samples, and
this was correlated with the traditional prognostic indicators, such as tumor grading and
Dukes’ staging (Maeda et al., 2003). Similarly, TCF4 was found to be hypermethylated
in colon cancers and hypermethylation was found to be high in stage I/II than in stage
III/IV in gastric cancer (Kim et al., 2008). For many epigenetically silenced genes, re-
expression in tumor cells can lead to suppression of cell growth or altered sensitivity to
existing anticancer therapies and small molecules that reverse epigenetic inactivation
like demethylating drugs are now undergoing clinical trials in cancer patients
(Momparler et al., 1997; Pohlmann et al., 2002) to reverse the silencing of genes
resulting from methylation (Strathdee et al., 1999; Plumb et al., 2000) Thus, epigenetic
alterations are not only potential therapeutic targets because of their reversibility, but
also potential biomarkers that can be used to detect and diagnose cancer in its earliest
stages (Brown et al., 2002). This potential to reverse DNA methylation and re-express
the affected critical genes presents an attractive option for exploring clinical use in
malignancies. The commonly used drugs targeting methylation are azacytidine (5-
azacytidine), decitabine (5-aza-2-deoxycytidine), fazarabine (1-D-arabinofurasonyl-5-
azacytosine), and dihydro-5 azacytidine (Goffin and Eisenhauer, 2002). HDAC
inhibitors are also being tried as potential chemotherapeutic agents (Thiagalingam et
al., 2003) as DNA methylation represses gene expression in part through histone
deacetylation, HDAC inhibitors have been used to activate expression from methylated
genes but these work together with demethylating agents (Cameron et al., 1999).
Preclinical studies on decitabine have shown that it reverses methylation in a number of
cell lines and in cells from human leukemia patients (Wilson et al., 1983; Momparler et
al., 1984).
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2.1.8 TCF4 Gene
TCF4
The Transcription factor 4
 HLHb19
 Class B basic helix
 E2-2
 ITF2
 SEF2
The tcf4 protein is encoded by
base pairs 52,889,561 to 53,255,859 on chromosome 18.
are alternative 5' exons si
figure 4.
Fig 4: Cytogenetic Location:
of chromosome 18 at position 21.1).
The tcf4 protein
role in the maturation of cells to carry out specific functions
apoptosis. The lowest quantities of
and colon. The highest levels are present in fetal brain, but
also in adult brain and is required for adult tissue maintenance in bone, heart, muscle.
Nevertheless, it seems that for production of sufficient amounts of
normal development, the presence of all transcription
The Transcription factor 4 gene
loop-helix (bHLH) family
functional criteria , bHLH family of transcription factors is categorized into
various classes and each member protein contains an HLH domain and a
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also known by other names:
-loop-helix protein 19
TCF4 gene. Molecular Location on chromosome 18:
It has 41 exons of which 21
tuated at various positions throughout the gene as depicted in
18q21.1 (The TCF4 gene is located on the long (q) arm
(Source Wikipedia)
shows its expression before birth in various tissues
like cell differentiation and
tcf4 transcripts were present in fetal liver, pancreas
expression remains elevated
initiation sites
product is a member of the class I
(Masaari et al., 2000). On the basis of biochemical and
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. It plays a
tcf4 protein and
are important.
basic helix-
basic
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DNA binding domain, at its N-terminal site to make contact with consensus DNA
sequences known as E-boxes (CANNTG) , found in the promoters of various important
genes , driving their specific activation (Church et al, 1985 ; Murre et al,1994; Saisanit
and Sun, 1995; and Naya et al.,1995; Atchley and Fitch, 1997 and Ledent et al., 2002).
E-proteins are critical regulators in a diverse array of biological processes
such as cell growth, differentiation, tissue-specific gene expression, and
programmed cell death (Pagliuca, 2000; Massari et al, 2000; Jones, 2004 ) ,these can
form homodimers and heterodimers with other classes of bHLH proteins
through the HLH domain to facilitate binding to DNA (Murre et al., 1989) and
this dimerization regulates tissue-specific gene expression like differentiation and
proliferation of myocytes (Lassar et al., 1991), osteoblasts (Beck et al., 2001), B and T
lymphocytes (Quong et al., 2002), and neuronal cells (Persson et al.,2000) through E-
box sites . These E-proteins function as transcription activators or repressors.
Exon 1 of TCF4 has β –catenin binding domain, exon 10 and 11 has DNA
binding HMG boxes and exon 17 has COOH terminal binding domain. Previous studies
have presented controversial cellular roles for TCF4 (Pagliuca et al., 2000 and Kolligs
et al., 2002). It has also been established that TCF4 silencing was more frequent in
early stage gastric cancers than in advanced stage gastric cancers, besides its silencing
is associated with cell growth and migration in gastric cancer cell line. TCF4 is a end
product of Wnt signaling pathway (Behrens et al., 1996; Korinek et al., 1997), and
plays an important role in malignant transformation (Cadigan et al., 1997). c- myc,
cyclin D1, c-Jun, MMP7 are targets for Wnt pathway. Mutations in this pathway in
adults contribute to degenerative diseases and cancers. The β -catenin / TCF4 complex
imposes a crypt progenitor phenotype on colorectal cancer cells and maintains the
undifferentiated state of intestinal crypt progenitor cells (Van Es et al., 2005). Thus the
β –catenin /TCF4 constitutes the master switch that controls proliferation versus
differentiation in healthy and malignant intestinal epithelial cells. The TCF4 target gene
c myc plays a central role in this switch by direct repression of p21 (CIP/WAF12
promoter) (Van de watering et al., 2002). It has also been shown that the enforced
expression of TCF4 suppresses the colony-forming efficiency of cells in
several cell lines, suggesting its role as a negative regulator of
cell proliferation (Pagliuca et al., 2000). The loss of epithelial cell polarity may also
contribute to intestinal tumorogenesis (Naishiro et al., 2001).
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TCF4 is critical for nervous system functioning as its mutation causes PHS
(Brockschmidt et al., 2007; Amiel et al., 2007 and Zweier et al., 2007), a
neurodevelopmental disease characterized by mental retardation, seizures, and
hyperventilation (Pitt and Hopkins., 1978 and Peippo et al.,2006) and also SNP of
TCF4 in exon 17 are observed in Renal cell carcinoma (Hiroaki Shiina et al.,
2003).Mutation of TCF4 is also found in gastric cancer and breast cancer ( Burwinkel
et al., 2006; Kim et al., 2009; Kojima et al.,2011). And these mutations is found to
enhance cell growth in various cell lines like in Primary CRCs , so making it as a tumor
suppressor gene ( Sjoblom et al., 2006; Wood et al.,2007; Tang et al.,2008). However.
the size of the mutation does not appear to affect the severity of the disease as people
with large deletions and those with single nucleotide changes seem to have similar
signs and symptoms. One study also revealed that silencing of TCF4 caused significant
sensitization of CRC cells to clinically relevant doses of X- rays ( Kendziorra et al.,
2011). TCF4 gene’s inability to bind to DNA and control the activity of genes involved
in nervous system development and function, and genes like cyclin D1, c myc ,c jun,
etc involved in cell cycle functions contributes significantly to the signs and symptoms
of Pitt-Hopkins syndrome and significantly to carcinogenesis.
DNA methylation and modification of chromatin structure often
occur in neoplasia. Aberrant methylation of CpG islands in the promoter
regions and in the initial exons of many genes occurs in the early stages of
carcinogenesis and results in suppressed expression of a variety of genes in a diverse
array of cancers (Estellar, 2002; Herman and Baylin, 2003). Many reports have also
shown that methylation of CpG islands of TCF4 gene leads to its inactivation
particularly in gastric cancer (Grady et al.,2000; Shim et al., 2000 ; Iida, 2000; Oue
et al, 2001 and Kim et al.,2006). TCF4 is considered as age related as well as ca
specific methylated gene (Type A & C) in Gastric cancer. Gastric cancer the second
main cause of death in almost every country (Parkin et al., 2005), is not diagnosed until
at an advanced stage. Therefore, identification of effective biomarkers for early-stage
detection of gastric cancers is needed. In this study, the aberrant promoter
hypermethylation of TCF4 gene in gastric cancer was demonstrated. The result
suggested that promoter hypermethylation of this gene plays an important role in
gastric tumorigenesis.
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A case-control study was undertaken to understand the etiology of gastric
cancer in Kashmir valley: A state with high incidence of this dreadful disease. All
ethical considerations were taken care of during the study and the recruitment process
was started only after ethical clearance by the Departmental Ethical Committee as per
norms. Subjects with histopathologically confirmed gastric carcinoma tissue samples
and histopathologically confirmed gastric normal tissue samples were evaluated.
Histopathologically confirmed gastric cancer tissue samples were cases while as
histopathologically confirmed normal tissue samples were treated as controls. The
samples were collected from Department of Surgery, Shri Maharaja Hari Singh
Hospital associated with Government Medical College, Srinagar J&K. The sample size
was 80 out of which 50 were cases and 30 controls. Record of complete case history of
patients was maintained.
3.1 CASES
Samples of gastric cases patients that were operated in the Department of
Surgery, S.M.H.S. Hospital, Srinagar, and Private administered Hospitals were
included in the study. During the study, cases were included irrespective of their age
and stage of the cancer.
3.1.1 Inclusion Criteria
The diagnosis of gastric cancer was based on the standard histopathological criteria.
The criteria for including a subject as case in the study were:
 All histopathologically confirmed patients irrespective of cancer stage and age.
 Patients of Kashmiri origin.
3.1.2 Exclusion Criteria
Under the following conditions the patients were not recruited in the study:
 Patients suffering from any other disease
 Patients who had received prior chemo or radiotherapy
 Patients not of Kashmiri origin
 Any other type of cancer
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3.2 CONTROLS
Resected gastric samples from the Department of Surgery, S.M.H.S. Hospital which
were histopathologically confirmed as normal were processed as controls.
3.2.1 Inclusion criteria
 Patients of Kashmiri origin.
3.2.2 Exclusion criteria
 Patients who suffered from any kind of malignancy.
 Patients not of Kashmiri origin.
3.3 COLLECTION OF TISSUE SAMPLES
The case and control samples were put in plastic vials (50 ml volume) and the
vials were properly labeled, to avoid possible mixing of sample vials and for easy
retrieval of the required sample vial. The collected samples were divided into two parts
and one was kept in 10% formalin for histopathological evaluation and other part in
normal saline and was kept at -80 ºC for further analysis. Histopathological report of all
the collected samples were collected before they were further processed. Records were
maintained carrying information regarding gender, age, history of disease, etc.
3.4 GENETIC ANALYSIS
3.4.1 Extraction of genomic DNA
For the isolation of genomic DNA, kit based method was used. The kit used was
Quick- g DNATM Mini Prep supplied by ZYMO RESEARCH. The protocol followed
was as directed by the company.
The DNA extracted was stored at 4 º C for a short duration but the vials were kept at -
20oC for longer duration storage for further investigation.
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3.4.2 QUALITATIVE AND QUANTITATIVE ANALYSIS OF GENOMIC DNA
3.4.2.1 Qualitative Analysis
The integrity of the genomic DNA was examined by gel electrophoresis using 1
% agarose gel to which 10µl/ 50ml (of gel solution) of fluorescent dye ethidium
bromide was added during its cooling. The gel was cast and 20µl wells were made into
it by using suitable combs. 2µl of each DNA sample was mixed with 1µl of 1X DNA
loading dye (4.16 mg bromophenol blue, 4.16 mg xylene cyanol and 0.66g sucrose) and
was loaded in the gel. Electric current was applied at 50 volt until DNA entered in to
the gel and potential was raised to 70 volt for rest of the run. Run was stopped when the
dye had travelled nearly two- third of the gel. DNA in the gel was visualized with the
help of Gel doc system (Alphaimager TM 2200, Alpha Innotech Corporation) under
UV light and picture was captured by using CCD camera system.
3.4.2.2 Quantitative Analysis
The quantity of the DNA was determined by measuring optical density
(Absorbance) at 260nm and 280 nm using double beam spectrophotometer (Evolution
60S from Thermo Scientific) and the concentration was determined by using the fact
that absorbance of 1 unit equates to 50µg/ ml and therefore, the concentration of DNA
sample was determined by the following equation
DNA (µg/ml) = A260 x 50 x dilution factor
Dilution factor (D.F). = volume of final diluted solution/volume of original
concentrated solution.
The purity of DNA was estimated by obtaining the ratio of values of absorbance at 260
and 280.
Ratio = A260 /A280
The ratio of A260/A280 was calculated and the DNA sample for which the ratio was 1.7-
1.9 was considered suitable for the future use. DNA was alliqouted into three to four
tubes so as to protect damage from freeze thawing and store at -20 ºC freezer for longer
duration of time.
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3.5 DNA MODIFICATION (BISULFITE TREATMENT)
The above extracted Genomic DNA was modified by EZ DNA Methylation
DirectTM Kit supplied by ZYMO RESEARCH. The protocol followed was as directed
by the company.
Sodium bisulfite treatment
in figure 5. DNA, however, remains unmodified at places where DNA was methylated.
This modification can help us differentiate between methylated and unmethylated DNA
using specific primers i
or can be stored at or below
Fig. 5: Diagrammatic representation of cytosine conversion to uracil
3.6 METHYL SPECFIC POLYMERASE CHAIN REACTION (MSP)
To determine the status of
Kashmir valley, Methyl Specific PCR (MSP)
TCF4 gene in 50 surgically resected gastric cancer DNA and compared with that of 30
histopathologically confirmed normal gastric tissues.
for detection of hypermethylation in CpG islands of DNA
The principle of this PCR method
hypermethylated and non
converted unmethylated cytosines
n MS-PCR. Now DNA can be subjected to immediate analysis
-20ºC for later use.
TCF4 promoter methylation in gastric cases from
was performed for a promoter region of
MSP is a novel and sensitive way
.
lies in the amplification of the
-methylated DNA of the same gene by different primer
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to uracil as shown
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sequence; one for hypermethylated version of the gene and one for the non-methylated
version of the same gene. Table 2 shows unmethylated and methylated sets of primers
of TCF4 gene. Thus by visualising the PCR product we can easily determine whether
amplification is by hypermethylated or non-methylated primers, thus determine
whether our CpG’s were hypermethylated or unmethylated. The methylated cytosine
pairs with guanine and unmethylated modified to uracil (C converted to U) pairs with A
during annealing.
The modified DNA was taken into two PCR vials in equal quantity and same
amount of all reagents (Table 3) was added to both the vials but in one vial methylated
primers were used and in second vial non-methylated primers were used.
PCR amplification was achieved using a Thermal cycler (Gradient thermal
cycler from (EPPENDORF MASTERCYCLER PRO). Reactions were hot-started at
95ºC for 5 min, followed by addition of Taq Polymerase, followed by 35 cycles of
melting (95ºC for 45 sec.), annealing (59ºC for 45 sec.) and extension (72ºC for 45
sec.) and by final extension step at 72º C for 4 min (Table 4).
Universal Methylated Human DNA Standard and Control with primers (ZYMO
RESEARCH) was used as positive control, and water was used as negative control.
Each PCR reaction (10 μl) was directly loaded onto non denaturing 2% agarose gel,
stained with ethidium bromide, and visualized under UV illumination.
The amplified DNA were of approximately same base pairs in length, the methylated
and the unmethylated PCR product were of 258 bp and 259bp and were then
visualized under UV light in presence of a 100 bp DNA ladder run parallel to the
amplified PCR products on 2% ethidium bromide pre-loaded agarose gel.
3.7 STATISTICAL ANALYSIS
The χ
2-test with Odds ratio was used to examine the association between
hypermethylation of TCF4 gene and cancer in gastric samples in a case-control study.
ORs with 95% CIs were computed using unconditional logistic regression using Graph
Pad Prism Software Version 5.0 by Graph Pad Software 2236, Avenida de la Playa, La
Jolla, CA 92037, USA.
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Table 2: The DNA sample was amplified using the following primer pairs, two for
each gene (Kim et al., 2008).
Nature of
Sequence
Primer sequence
UNMETHYLATED
PRIMER
Forward
primer
5’- TGA ATT TGT STTT GTG TGT TTT T G-3’
Reverse
primer
5’- AAA AAA AAC TCT CCA TAC ACCACC-3’
METHYLATED
PRIMER
Forward
primer
5’- GAA TTT GTA ATT TCG TGC GTT TC-3’
Reverse
primer
5’- AAA AAA AAC TCT CCG TAC ACC G-3’
Table 3: Volume and concentrations of different reagents used in PCR
Reagent Volume
1 X Taq buffer 2.5 µl
dNTPs (1.25mM) 1.25 µl
Forward primer (150 ng/ reaction) 1 µl
Reverse primer (150 ng/ reaction) 1 µl
Template DNA(50 ng/ reaction) 1.25 µl
Taq DNA Polymerase( 5U/ µl ) 0.2 µl
De ionised water 17.8 µl
Table 4: Thermal cycling conditions
Steps Temperature0C Time Number of
cycles
1. Hot-Start 95 5 min 1
2. Denaturation 95 45 sec
353. Annealing 59-61 45 sec
4. Extension 72 45 sec
5. Final extension 72 4 min 1
CHAPTER: 4
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4.1 Methylation status of TCF4 gene in cases and control
4.1.1 Cases
In the present study 50 histopathologically confirmed gastric cancer cases
belonging to Kashmir division were analyzed for promoter region hypermethylation of
TCF4 gene. Out of 50 cases 33 were males which correspond to 66% and remaining 17
were females which correspond to 34%. The patients of gastric cancer belonged to
different regions of Kashmir valley. Most often cancer was diagnosed at a stage when
the disease was less likely to be cured.
4.1.2 Controls
Thirty histopathologically confirmed normal gastric cancer tissues were analyzed
and taken as controls. Out of 30 normal cases 15 were males and remaining 15 cases
were females.
4.1.3 Extraction of genomic DNA
Genomic DNA was isolated by kit method. Genomic DNA was isolated from
all 80 samples (50 cases and 30 controls)
4.1.4 Qualitative analysis
The integrity of the genomic DNA isolated from tissue samples was examined
on 1% agarose gel. Representative gel picture is given in figure 6.
4.1.5 Quantitative analysis
Quantity of the DNA was determined by using double beam spectrophotometer
(Evolution 60 S from Thermo Scientific) and following equation is used to determine
concentration
DNA (µg/ml) = A260 x 50 x dilution factor
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Fig 6: Representative gel picture showing the integrity of the genomic DNA on 1%
agarose gel Lane 1 to 4 contains the genomic DNA isolated from the tissue
samples of gastric cancer cases (GC1 to GC 4) and Lane 4 to 8 contains the
genomic DNA isolated from the tissue samples of gastric normals (controls)
(N1 to N4)
4.2 ANALYSIS OF TCF4 GENE PROMOTER HYPERMETHYLATION IN
CASES AND CONTROLS
To determine the status of TCF4 promoter hypermethylation in gastric cancer
cases from Kashmir valley, the MS-PCR for the promoter region (exon 1) of TCF4
gene in 50 surgically Resected gastric cancer DNA was performed and compared with
that of 30 histopathologically confirmed normal gastric tissues. Primers described (Kim
et al., 2008) were used to discriminate between methylated and unmethylated DNA
following bisulfite treatment. The amplicons were analysed on 2% agarose gel.
Amplification was carried out using hot start PCR method, this decreases the non
specific amplifications. The methylated and unmethylated PCR products were of 258
and 259 bp respectively. Gastric cancer samples were amplified by using both
methylated and unmethylated set of primers in MS- PCR as shown in fig7, but cases
were found to be amplified by methylated primers only, indicating that gastric cancer
cases show TCF4 promoter hypermethylation. Similarly, histopathologically confirmed
normals were amplified by using both types of primers i.e., methylated and
unmethylated ones as shown in fig 8, but the samples were found to be amplified by
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unmethylated primers only, indicating that normal samples do not show promoter
hypermethylation of TCF4 gene. In addition, fig 9, shows normal samples amplified by
unmethylated set of primers only, further indicating that normals do not show promoter
hypermethylation.
As far as the frequency is concerned, 66% (33/50) of the gastric cancer tissues
were found to have methylated TCF4 promoter and 34% (17/50) of the cases had
unmethylated TCF4 promoter. The data depicted in table 5. In normal gastric tissues,
80% (24/30) of the normals were found to have unmethylated promoter and 20% (6/30)
had methylated one. The results are given in table 6.
The association of promoter hypermethylation with gastric cancer was
evaluated using Chi-square test and was found to be significant (p=0.0002, Odds ratio =
7.765, 95% C.I= 2.66- 22. 62) as depicted in fig 10.
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Table 5: Data representing no. of cases showing promoter hypermethylation and
non-hypermethylation during MSP amplification in gastric cancer cases
confirmed by 2% agarose gel electrophoresis
CASES (50)
PARAMETER CASES FREQUENCY
HYPERMETHYLATED 33 66% (33/50)
NON HYPERMETHYLATED 17 34% (17/50)
Table 6: Data representing no. of cases showing promoter hypermethylation and
non-hypermethylation during MSP amplification in histopathologically
confirmed normal cases confirmed by 2% agarose gel electrophoresis
CONTROLS (30)
PARAMETER CASES FREQUENCY
HYPERMETHYLATED 6 20% (6/30)
NON HYPERMETHYLATED 24 80% (24/30)
Odds ratio = 7.765, 95% C.I= 2.66-22.62, p = 0.0002
(Statistically significant p<0.05)
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Fig 10: Histogram representing hypermethylated and non hypermethylated cases
of gastric cancer and histopathologically confirmed normal controls
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4.3 Relationship between promoter hypermethylation of TCF4 gene and in males
and females
Occurrence of TCF4 methylation was found to be unequally distributed in
males and females with more frequency in males than in females. Among 33 males, 22
cases were hypermethylated and 11 were unhypermethylated and among 15 male
controls, 4 cases were hypermethylated and 11 were unhypermethylated shown in
Table no 7. The association of promoter hypermethylation with gastric cancer was
evaluated using Fisher’s exact test and was found to be significant in males (O.D=5.5,
95% C,I=1.4-21.31 p=0.023),shown in fig 11. In comparison, among 17 females, 11
cases were hypermethylated and 6 Cases were unhypermethylated and among 15
females controls 3 Cases were hypermethylated and 12 Cases were unhypermethylated
as shown in Table 8. The association of promoter hypermethylation with gastric cancer
was evaluated using Fisher’s exact test and was found to be significant in females too
(O.D=7.33, 95% C,I=1.4-36.68 p=0.0287) shown in figure 12 .However on comparing
the male cases with female cases, 22 cases were hypermethylated and 11 Cases were
unhypermethylated in males and 11 cases were hypermethylated and 6 cases were
found to be unhypermethylated in females (Table 9),occurrence of TCF4 was found to
be unequally distributed in males than in females but the difference was not statistically
significant(O.D=0.916,95% C,I=0.26- 3.31,p=0.08599),shown in figure 13.The
hypermethylation status of TCF4 in males 66.66% (22/33) was also found to be higher
than females 64.70% (11/17) in cases.
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Table 7: Data representing no. of cases showing promoter hypermethylation and
non-hypermethylation in male gastric cancer cases and male controls
during MSP amplification confirmed by 2% agarose gel electrophoresis
MALES CASES (33)
PARAMETER CASES FREQUENCY
HYPERMETHYLATED 22 66.66% (22/33)
NON HYPERMETHYLATED 11 33.33% (11/33)
MALE CONTROLS (15)
PARAMETER CONTROLS FREQUENCY
HYPERMETHYLATED 4 26.66% (4/15)
NON HYPERMETHYLATED 11 73.33% (11/15)
Odds ratio = 5.5, 95% C.I= 1.4-21.31, p = 0.0023
(Statistically significant p<0.05)
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Table 8: Data representing no. of cases showing promoter hypermethylation and
non-hypermethylation in female gastric cancer cases and female controls
during MSP amplification confirmed by 2% agarose gel electrophoresis
FEMALE CASES (17)
PARAMETER CASES FREQUENCY
HYPERMETHYLATED 11 64.70 % (11/17)
NON HYPERMETHYLATED 6 35.29% (6/17)
FEMALE CONTROLS (15)
PARAMETER CONTROLS
FREQUENCY
HYPERMETHYLATED 3 20% (3/15)
NON HYPERMETHYLATED 12 80% (12/15)
Odds ratio = 7.33, 95% C.I= 1.4-36.68, p = 0.0287
(Statistically significant p<0.05)
Chapter 4 Results
38
Fig 12: Histogram representing hypermethylated and non hypermethylated
female gastric cancer cases and histopathologically confirmed normal
female cases.
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Table 9: Data representing no. of cases showing promoter hypermethylation and
non-hypermethylation in male and female gastric cancer cases during
MSP amplification confirmed by 2% agarose gel electrophoresis
MALES CASES (33)
PARAMETER CASES FRQUENCY
HYPERMETHYLATED 22 66.66% (22/33)
NON HYPERMETHYLATED 11 33.33% (11/33)
FEMALES CASES (17)
PARAMETER CASES FREQUENCY
HYPERMETHYLATED 11 64.70% (11/17)
NON HYPERMETHYLATED 6 35.29% (6/17)
STATISTICAL ANALYSIS: Using chi square test
Odds ratio = 7.33, 95% C.I= 1.4-36.68,
p 08 (Statistically insignificant p>0.05)
p=0.p= .
Histogram representing hypermethylated
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Fig 13: and nonhypermethylated male
and female confirmed normal female cases.
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Gastric Cancer, the fourth most common cancer after lung cancer in the world,
shows its high incidence in Japan, Iceland, China and other developing countries.
Gastric cancer is an asymptomatic disease as it is not diagnosed in early stages which
makes it the second most cause of cancer related deaths in the world. Gastric cancer is
thought to result from a combination of environmental factors and the accumulation of
generalized and specific genetic alterations, and consequently affects mainly older
patients often after a long period of atrophic gastritis. Multiple genetic and epigenetic
alterations are responsible for the development and progression of gastric cancer
(Zheng et al., 2004), like activation of oncogenes, overexpression of growth
factors/receptors, inactivation of tumor suppressor genes, DNA repair genes and cell
adhesion molecules, and abnormalities of cell cycle regulators that define biological
characteristics of cancer cells. Kashmir has a greater gastric malignancy rate with the
frequency of 50-60 cases per 100000 persons & 63% of these occur in southern district
of Kashmir.
Epigenetic mechanisms of gene inactivation, including promoter
hypermemethylation, are undoubtedly important in cancer development and represent
an alternative means of inactivating genes by transcriptional silencing mechanism.
Epigenetics is a growing field of research. Transcriptional silencing by CpG island
hypermethylation affects genes involved in all aspects of cell function and now rivals
genetic changes that affect coding sequence as a critical trigger for neoplastic
development and progression (Jones and Laird, 1999; Baylin and Herman, 2000). Gene
promoter hypermethylation has become a target for developing strategies to provide
molecular screening for early detection, diagnosis, prevention, treatment, and prognosis
of cancer. The effectiveness of gene promoter hypermethylation for cancer screening
and diagnosis ideally requires genes whose dysfunction early in tumor development,
are specific to a particular cancer, and a biological fluid or access to tissue that is
specific to the disease being assessed. For the majority of cancers, it is difficult to meet
of three of these criteria. This approach involves the detection of gene promoter regions
that are aberrantly hypermethylated in human tumors. This change is associated with an
epigenetically mediated gene silencing that constitutes an alternative to coding region
mutations for loss of gene function (Jones and Baylin, 2002; Herman and Baylin,
2003).
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Nevertheless, the standard of proof for establishing that hypermethylation of the
promoter of any given gene has a critical role in loss of gene expression and cancer
development should probably be set quite high, regardless of whether the gene is a well
established tumor suppressor gene, cell cycle regulatory gene, etc. So, in order to
confirm this fact, it is worth evaluating the data a bit more critically.
The current study was thus aimed at understanding
 The promoter hypermethylation status of TCF4 gene of Gastric cancer subjects
of Kashmiri origin and their correlation with histopathologically confirmed
controls.
DNA methylation involves addition of a methyl group to the carbon 5 position of
the cytosine ring, catalyzed by DNA methyltransferases using S-adenosylmethionine
as the donor molecule. The chromatin structure is modified during gene silencing by
affecting acetylation, phosphorylation, methylation, ubiquitylation of histone tails
(Jones and Baylin, 2002 ; Kelly et al., 2002). The rapid advance in the study of gene
promoter hypermethylation in cancer was facilitated by the development of the
Methylation Specific PCR (MSP) assay that allows for rapid detection of methylation
in genes through the selective amplification of methylated alleles within a specific gene
promoter (Herman et al., 1996). In the present study MSP was used for analysis of the
methylation status of TCF4 gene.MSP is much more sensitive than southern analysis,
facilitating the detection of low members of methylated alleles and the study of DNA
from small samples. Fresh human tumor samples often contain normal and tumor
tissue, making the detection of changes specific for the tumor difficult. However, the
sensitivity of MSP suggests that it would be useful for primary tumors as well, allowing
for detection of aberrantly methylated alleles even if they contribute relatively little to
the overall DNA in a sample.
In the present study, 50 histopathologically confirmed cancer cases and 30
histopathologically confirmed normal cases as controls were analyzed. Out of 50 cases,
33 were males which corresponded to 66% and hence remaining 17 were females
corresponded to 34%. Hence Males: Females ratio was 1.94. However, among normal
cases 15 were males and 15 were females with male to female ratio of 1:1. All the
patients were symptomatic at the time of diagnosis.
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The relationship between the promoter hypermethylation of TCF4 gene with
gender was observed. Occurrence of TCF4 methylation was found to be unequally
distributed in males and females with more frequency in males than in females. Among
33 males, 22 cases were found to be hypermethylated and 11 cases were unmethylated.
In 33 methylated samples 5 samples were amplified with both sets of primers
(methylated as well as unmethylated ones). This can be explained by the fact that
excised tissue sample might be containing some unaffected tissue beyond cancer
affected zone. However among 15 male controls 3 cases were hypermethylated and 12
were unmethylated. And among 17 female controls 11 cases were hypermethylated and
6 cases were unmethylated. The association of promoter hypermethylation with gastric
cancer was found to be significant in males (p= 0.0025) as well as in females too (p=
0.0028). Also on comparing the male cases with female cases, 22 cases were found to
be hypermethylated and 12 cases were unmethylated. The occurrence of TCF4
methylation was found to be unequally distributed in males and females with more
frequency in males than in females but the difference was not statistically significant
(p= 0.08). The controls in both males and females show hypermethylation in some of
the samples, this might be attributed to the contamination of non neoplastic cells with
cancerous tissue or it might also predict precancerous lesions occurring in these patients
or may also predict indication of metastasis. The low prevelance of gastric cancer in
females than males may be contributed to high estrogen levels in females as it was
observed that male rats are more prone to develop gastric cancer than females, but
tumor numbers become similar after male rats are treated with estrogen (Furukawa et
al., 1982)
The study also indicated high degree of association between gastric cancer and
promoter hypermethylation of TCF4 as study showed that more than 50% tissues were
found to be expressed methylated TCF4 promoter. Therefore, it is quite possible that
like other geographical regions, methylation of promoter of TCF4 gene is might be the
major epigenetic event in gastric cancer in the Kashmir valley.
The evidence of methylation in control suggests its role in diagnosis.
Premalignant detection of hypermethylation in gastric cancer patients have highlighted
the potential importance of TCF4 gene in early diagnosis as it was observed that
promoter hypermethylation of TCF4 gene was high in Stage I/II of patients than
patients having disease in advanced age (Kim et al., 2008).So, detection of methylation
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might represent the stage at which cancer may be in its course of development.
Occurrence of methylation in individuals without diagnosed cancer might indicate that
the patients may be in precancerous stage and so without further delay treatment can be
made. Thus the current and previous studies lead us to conclude that mass evaluation of
methylation status of this important gene could help and even prevent cancers well
before they can be symptomized and diagnosed.
The rapeutic strategies targeting promoter hypermethylation may be highly
beneficial in the Kashmiri population and other specific regions where incidence of
gastric cancer is associated with high frequency of TCF4 promoter hypermethylation.
In summary, this is the first observational study to examine the status of promoter
hypermethylation of TCF4 gene in gastric cancer patients of Kashmir valley. The study
revealed that urban life style may have a role in the development of this particular type
of cancer as majority of the cases were from the main urban cities of the Kashmir
valley i.e. Srinagar and Budgam.
The data thus gives a clue that TCF4 gene expression can be readily and fully
restored and growth rate of cancer cells decreased by treatment of cancer cells with
demethylating agents and DNA methylation inhibitors. The administration of drugs
such as cytosine analogs might be able to restore the function of TCF4 gene and slow
down the rate of gastric cancer progression. It also demonstrates that hypermethylation
of TCF4 gene can be designated as epigenetic biomarker for screening, diagnosis and
prognosis of gastric cancer.
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APPENDIX
APPENDIX
CHEMICALS AND REAGENTS
CHEMICALS
Chemical Name Company
Absolute ethanol BENGAL CHEMICALS
Acetone GALAXO LABORATORIES
Agarose MP BIOMEDICALS
Ammonium chloride BDH
Ammonium acetate BDH
Bromophenol blue SARABHAI M CHEMICALS
Chloroform THOMAS BAKERS
De Ionized water ALFA LABORATORIES
Ethidium bromide SRL
Ethyl acetate MERCK
Ethylene diamine tetra acetate (EDTA) LOBA CHEMIE
Formaldehyde GALAXO LABORATORIES
Glacial Acetic acid MERCK
Hydrochloric acid S D FINE CHEMICALS
Hydrogen peroxide MERCK
8-Hydroxyquinoline CDH
Isoamyl alcohol BDH
Isopropanol THOMAS BAKERS
Magnesium chloride MERCK
Methanol SARABHAI M CHEMICALS
Phenol SRL
Potassium acetate QUALIGENS
Potassium bicarbonate QUALIGENS
Potassium chloride LOBA- CHEMIE
Potassium hydroxide S D FINE CHEMICALS
2-Propanol MERCK
Sodium acetate SARABHAI M CHEMICALS
Sodium azide LOBA CHEMIE
Sodiun bisulphate LOBA CHEMIE
Sodium carbonate FIZMERCK
Sodium chloride MERCK
Sodium dodecyl sulphate MP BIOMEDICALS
Sodium hydroxide HIMEDIA
Sodium hydrogen carbonate LOBA- CHEMIE
Sodium phosphate dibasic LOBA- CHEMIE
Sodiun thiosulfate LOBA CHEMIE
Sucrose QUALIGENS
Sulfuric acid MERCK
TE buffer SRL
Tris base SIGMA CHEMICAL COMPANY
Tris HCL HIMEDIA
Triton X 100 S D FINE CHEMICALS
ENZYMES
Taq polymerase FERMENTAS / BIOTOOLS
Proteinase K ZYMO RESEARCH
MISCELLANEOUS MATERIAL
100bp DNA ladder FERMENTAS / BIO ENZYME
PCR REAGENTS
10 X Buffer (with Mgcl2) BIOTOOLS
dNTPs CINNAGEN
Primers (methylated and unmethylated) GENESCRIPT
Universal Methylated Human DNA
Standard and Control with primers
ZYMO RESEARCH
DNA Isolation:
DNA was isolated by kit based method. The kit used was Quick- g DNATM MiniPrep
supplied by ZYMO RESEARCH. Kit protocol was followed for DNA isolation.
DNA storage buffer:
0.5 M EDTA 0.01 ml
1 M Tris 0.5 ml
Final volume was made 50 ml with sterile distilled water.
DNA Bisulfite Modification:
DNA was modified by kit based method, the kit used was EZ DNA MethylationTM
Kit supplied by ZYMO RESEARCH. Kit protocol was followed for bisulfite
modification of isolated DNA.
REAGENTS FOR AGAROSE GEL ELECTROPHORESIS:
Agrose 1 % / 2%:
Agarose 0.5g / 1.0g
Buffer 50ml
Ethidium bromide 10µl
Agarose was dissolved in a buffer and heated till a clear solution is formed. Ethidium
bromide was then added to the solution during its cooling just before being poured into
the casting tray.
Bromophenol Blue:
Bromophenol Blue 0.4g
Sucrose 20.0g
Bromophenol blue was dissolved in 100ml of distilled water.
From the above stock solution 31.25ml was taken and sucrose was added. Final volume
was made 50ml with distilled water.
Ethidium Bromide
Ethidium bromide 10mg
Ethidium Bromide was dissolved in 1ml of distilled water. The solution was stored in a
dark bottle at 4˚C.
50-X TAE (pH 8.0) STOCK SOLUTION:
Tris base 242g
0.5M EDTA 100ml
Glacial acetic acid 57.1ml
Final volume was made 1000ml with distilled water. This is stock solution.
1-X TAE (pH 8.0) WORKING SOLUTION:
50-X TAE 20ml
Final volume was made 1000ml with distilled water.
Reagents for PCR:
Stock
Deoxyribose Nucleotide Triphosphate (dNTP) 100mM each dATP, dGTP, dCTP and
dTTP.
Taq polymerase (5U/µl)
10X Taq buffer (16 mmol/L Ammonium sulphate; 67 mM/L Tris- HCL, pH 8.8; 10
mM/L 2-Mercaptoethanol); 6.7 mM/ L MgCl2)
Primers: 100pM in sterile deionised water (Genescript)
100bp DNA ladder (0.5µg/µl)
